Orchard Therapeutics’ OTL-200 Receives Rare Pediatric Disease Designation from FDA for Treatment of Metachromatic Leukodystrophy Orchard’s fourth Rare Pediatric Disease Designation for autologous ex vivo gene therapy.
Orchard Therapeutics, a leading commercial stage company dedicated to transforming the lives of patients with rare diseases through innovative gene therapies, today a...
Continue Reading →
